Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 10/20 | 0.56 |
| ▸ | RXRA | P19793 | 6/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.52 |
| ▸ | MAPT | P10636 | 3/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.52 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.52 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.52 |
| ▸ | GLA | P06280 | 1/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | EDNRA | P25101 | 1/20 | 0.52 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.52 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.50 |
| ▸ | EGFR | P00533 | 1/20 | 0.50 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.50 |
| ▸ | DRD1 | P21728 | 1/20 | 0.50 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.50 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11882623 | 1.00 | PPARG (0.56) | PPARGRXRACYP1A2MAPTMAPK1 | |
| SCHEMBL11882613 | 1.00 | PPARG (0.56) | PPARGRXRACYP1A2MAPTMAPK1 | |
| SCHEMBL16188440 | 0.87 | PPARG (0.56) | PPARGRXRACYP1A2MAPTMAPK1 | |
| SCHEMBL13653162 | 0.87 | PPARG (0.56) | PPARGRXRACYP1A2MAPTMAPK1 | |
| SCHEMBL764389 | 0.87 | PPARG (0.56) | PPARGRXRACYP1A2MAPTMAPK1 | |
| SCHEMBL13653157 | 0.86 | PPARG (0.55) | PPARGRXRACYP1A2MAPTMAPK1 | |
| SCHEMBL13653161 | 0.86 | PPARG (0.55) | PPARGRXRACYP1A2MAPTMAPK1 | |
| SCHEMBL6881443 | 0.85 | PPARG (0.64) | PPARGRXRACYP1A2MAPTMAPK1 | |
| Sulindac SCHEMBL2029754 | 0.85 | PPARG (0.78) | PPARGRXRACYP1A2MAPTMAPK1 | |
| Sulindac SCHEMBL7939976 | 0.85 | PPARG (0.64) | PPARGRXRACYP1A2MAPTMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4272761-A2 | COMPOSITIONS FOR TREATING OPHTHALMIC CONDITIONS | Medicon Pharmaceuticals, Inc. (US) | 2023-11-08 | — | — | EP | disclosed |
| WO-2010009215-A1 | NICOTINIC ACID RECEPTOR AGONIST COMPOUNDS USEFUL TO TREAT METABOLIC SYNDROMES | SCHERING CORPORATION (US) | 2010-01-21 | — | — | WO | disclosed |
| WO-2010009212-A1 | NIACIN DERIVATIVES USEFUL TO TREAT METABOLIC SYNDROMES | SCHERING CORPORATION (US) | 2010-01-21 | — | — | WO | disclosed |
| US-20090326073-A1 | PROTECTION OF NORMAL CELLS | FLORIDA ATLANTIC UNIVERSITY | 2009-12-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090326073-A1 | PROTECTION OF NORMAL CELLS | ERCC1, ERCC2, XPA | PPARG 1026/4885RXRA 118/4885CYP1A2 966/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.